Quick Answer
Syndax Pharmaceuticals Inc reported Cash And Cash Equivalents At Carrying Value of $134.93 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed a decrease of -12.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Syndax Pharmaceuticals Inc's Cash And Cash Equivalents At Carrying Value has grown by 1,235.4%.
- Historical annual values: Fiscal year 2025: $134.93 million | Fiscal year 2024: $154.08 million | Fiscal year 2023: $295.39 million | Fiscal year 2022: $74.36 million | Fiscal year 2021: $221.97 million | Fiscal year 2020: $115.24 million | Fiscal year 2019: $24.61 million | Fiscal year 2018: $33.77 million | Fiscal year 2017: $35.17 million | Fiscal year 2016: $23.84 million | Fiscal year 2015: $23.18 million | Fiscal year 2014: $10.01 million | Fiscal year 2013: $10.10 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: